BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15995958)

  • 1. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection.
    Rosenblatt HM; Stanley KE; Song LY; Johnson GM; Wiznia AA; Nachman SA; Krogstad PA;
    J Infect Dis; 2005 Aug; 192(3):445-55. PubMed ID: 15995958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O; Holub M; Spála J; Kalanin J; Stanková M
    Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [T-cell subsets variation during clinical and immunological progression in vertically HIV-infected children].
    Resino García S; Bellón Cano JM; Navarro Caspistegui J; Gurbindo Gutiérrez D; León Leal JA; Muñoz-Fernández MA
    Medicina (B Aires); 2001; 61(5 Pt 1):557-65. PubMed ID: 11721322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART.
    Choremi-Papadopoulou H; Tsalimalma K; Dafni U; Dimitracopoulou A; Kordossis T
    J Med Virol; 2004 Jun; 73(2):235-43. PubMed ID: 15122798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non--rapid progressor children.
    Paul ME; Shearer WT; Kozinetz CA; Lewis DE
    J Allergy Clin Immunol; 2001 Aug; 108(2):258-64. PubMed ID: 11496243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.
    Benito JM; Lopez M; Lozano S; Ballesteros C; Capa L; Martinez P; Gonzalez-Lahoz J; Soriano V
    J Infect Dis; 2005 Dec; 192(12):2142-6. PubMed ID: 16288380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
    AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].
    Qiu ZF; Li TS; Ruan GR; Han Y; Xie J; Zuo LY; Li YL; Wang AX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):386-90. PubMed ID: 16900640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.
    Spritzler J; Mildvan D; Russo A; Asthana D; Livnat D; Schock B; Kagan J; Landay A; Haas DW;
    Clin Infect Dis; 2003 Aug; 37(4):551-8. PubMed ID: 12905140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
    Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
    J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths.
    Rosso R; Fenoglio D; Terranova MP; Lantieri F; Risso D; Pontali E; Setti M; Cossarizza A; Ravetti JL; Viscoli C; Kunkl A
    Scand J Immunol; 2010 Jan; 71(1):45-51. PubMed ID: 20017809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic features of HIV-1-infected women on HAART at delivery.
    Ono E; Dos Santos AM; Machado DM; Succi RC; Amed AM; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2008 Jul; 74(4):236-43. PubMed ID: 18393385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.